Publications by authors named "J J van Delden"

Aim: Perspective-taking is increasingly valued as an important competence to deliver person-centered care. It is conceptualized as a facet of cognitive empathy, but also connected to other attitudes and competences. Multiple studies report on educational interventions focused on perspective-taking, but an overview of instruments to measure perspective-taking is lacking.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how patients with advanced cancer cope over time, aiming to improve supportive care by understanding their coping strategies.
  • Data from 675 patients across six European countries were analyzed, using questionnaires to track Denial, Acceptance, and Problem-Focused coping over 20 weeks.
  • Findings showed that while most coping strategies remained stable, different subgroups of patients exhibited varying trajectories in their coping methods.
View Article and Find Full Text PDF

Introduction: While Learning Healthcare Systems (LHSs) have received increasing attention in health care and research, the amount of operational LHSs remains limited. Given the investment of resources in these projects, a moral responsibility to pursue the transition toward an LHS falls on projects and their participating stakeholders. This paper provides an ethics framework for projects that have taken steps toward building an LHS and are in the position to transition to an operational LHS.

View Article and Find Full Text PDF

The European Medicines Agency's conditional marketing authorization (CMA) aims to expedite patient access to medicines for unmet medical needs by shifting a part of the drug development process post-authorization. We highlight ethical issues surrounding CMA, comprising (i) the complexity of defining unmet medical need; (ii) poor understanding of CMA and its impact on informed consent; (iii) hope versus unrealistic optimism; (iv) implications of prolonged post-authorization studies and potential patient harm; (v) rights and duties of patients surrounding participation in post-authorization studies; (vi) access to previously authorized CMA medicines; and (vii) the "benefit slippage" phenomenon, defined as the gradual shift of strict criteria to less strict criteria. We propose a comprehensive research agenda to address these ethical issues, and stress the need for multi-stakeholder engagement to ensure patient-centered use of CMA.

View Article and Find Full Text PDF